0.5501

1.49% 0.0081

Traws Pharma Inc (TRAW)

Overview News Price History Discussions Forecast

Traws Pharma Inc stock is traded at $0.5501, with a volume of 67,291. It is up +1.49% in the last 24 hours and down -0.58% over the past month. Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.

Previous Close:

$0.542

Open:

$0.5711

24h Volume:

67,291

Relative Volume:

0.21

Market Cap:

$8.45M

Revenue:

$2.73M

Net Income/Loss:

$-19.43M

P/E Ratio:

-0.2419

EPS:

-2.2739

Net Cash Flow:

$-17.91M

1W Performance:

-6.75%

1M Performance:

-0.58%

6M Performance:

-67.26%

1Y Performance:

-66.96%

1-Day Range:

$0.5401

$0.5711

1-Week Range:

$0.5401

$0.61

52-Week Range:

$0.4301

$3.265

Traws Pharma Inc Stock (TRAW) Company Profile

Name

Traws Pharma Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

267-759-3680

Address

12 PENNS TRAIL, NEWTOWN

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

TRAW's Discussions on Twitter

Compare TRAW vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRAW Traws Pharma Inc	0.5501	7.99M	2.73M	-19.43M	-17.91M	-2.2739
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-25	Initiated	H.C. Wainwright	Buy
Mar-01-22	Initiated	Ladenburg Thalmann	Buy
May-18-21	Initiated	Guggenheim	Buy
Mar-01-18	Reiterated	H.C. Wainwright	Buy
Jan-17-18	Downgrade	Maxim Group	Buy → Hold
Oct-09-17	Initiated	H.C. Wainwright	Buy
Apr-27-17	Initiated	Laidlaw	Buy
Jul-01-15	Upgrade	Piper Jaffray	Neutral → Overweight
May-05-15	Initiated	H.C. Wainwright	Buy

View All

Traws Pharma Inc Stock (TRAW) Latest News

Aug 20, 2026

Traws Pharma prepares MHRA resubmission for influenza study - scanx.trade

Aug 20, 2026

Aug 19, 2026

H.C. Wainwright Maintains Traws Pharma(TRAW.US) With Hold Rating, Maintains Target Price $1 - Moomoo

Aug 19, 2026

Aug 18, 2026

Traws Pharma Ties Up To $50 Million Of Additional Financing To Influenza Regulatory And Clinical Milestones - Pulse 2.0

Aug 18, 2026

TRAW Reiterated by HC Wainwright & Co. -- Maintains Price Target at $1.00 - GuruFocus

Aug 18, 2026

H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 By Investing.com - Investing.com Nigeria

Aug 18, 2026

H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 - Investing.com

Aug 18, 2026

Aug 17, 2026

Traws Pharma shares rise after Q2 loss comes in better than expected - Yahoo Finance

Aug 17, 2026

Traws Pharma beats Q2 loss estimates, shares jump 4% By Investing.com - Investing.com South Africa

Aug 17, 2026

Traws Pharma beats Q2 loss estimates, shares jump 4% - Investing.com

Aug 17, 2026

TRAW Looks 95.6% Undervalued on GF Value™ Amid Price-to-Sales Co - GuruFocus

Aug 17, 2026